Author index

Abeler, V. See Raju, K.S., 69
Adcock, L.A. See Carter, J., 243
Agostini, H.J. See Nahhas, W.A., 259
Al Nafussi, A.I. See Blessing, K., 81
Al Nafussi, A. See Rahilly, M., 268
Atkin, N.B. see Haapasalo H., 155

Baiocchi, G. See Benedetti Panici, P., 133
Baracchini, P. See Lapertosa, G., 33
Bardi, G. See Pandis, N., 163
Battaglia, F. See Scambia, G., 253
Benedetti Panici, P. See Scambia, G., 253
Benedetti Panici, P., Scambia, G., Baiocchi, G., Greggi, S. & Mancuso, S. Technique and feasibility of radical para-aortic and pelvic lymphadenectomy for gynecologic malignancies: a prospective study, 133
Benediktsdottir, K. See Sigurdsson, K., 49
Berek, J.S. See Takami, C.Y., 97
Berger, M. See Tonkin, K.S., 185
Bichel, P., Jakobsen, A. & Ørntoft, T.F. Histochemical distribution of CA-125 as a prognostic indicator in patients with serous ovarian cancer, 199
Bichel, P. See Jakobsen, A., 195
Blackledge, G. See Redman, C.W.E., 215
Blake, P.R. See Hoskin, P.J., 75
Blake, P.R. See Moskovic, E., 125
Blessing, K., Kernohan, N.M., Miller, I.D. & Al Nafussi, A.I. Malignant melanoma of the vulva: clinicopathological features, 81
Bolis, G. See Trimbos, J.B., 89
Bonnar, J. See Gleeson, N., 223
Bouma, J. See Weijmar Schultz, W.C.M., 37
Bryson, S.C.P., Dembo, A.J., Colgan, T.J., Thomas, G.M., DeBoer, G. & Lickrish, G.M. Invasive squamous cell carcinoma of the vulva: defining low and high risk groups for recurrence, 25
Buckley, C.H. See Hale, R.J., 19, 233
Buckley, C.H. See Wilkinson, N., 285

Cabiddu, F. See Lapertosa, G., 33
Carson, L.F. See Carter, J., 243
Carter, J., Carson, L.F., Moradi, M.M., Adcock, L.A. & Twiggs, L.B. Pseudomyxoma peritonei: a review, 243
Chan, K.K. See Redman, C.W.E., 215
Chang, F. See Ji, H.X., 59
Chetsanga, C., Pettersson, B., Pettersson, U. & Gyllensten, U. Detection of human papillomavirus DNA in cervical smears by the polymerase chain reaction, 209
Clark-Pearson, D.L. See Steller, M.A., 41
Colgan, T.J. See Bryson, S.C.P., 25
Collan, Y. See Haapasalo, H., 155
Connelly, P.J. See Nahhas, W.A., 259
Cruickshank, D.J. CA125 parameters in survivors and non-survivors with epithelial ovarian cancer, 279

DeBoer, G. See Bryson, S.C.P., 25
Dembo, A.J. See Bryson, S.C.P., 25
Dembo, A.J. See Thomas, G.M., 1

Einarsson, G.V. See Sigurdsson, K., 49
Elit, L. See Holland, D.R., 227

Ferrandina, G. See Scambia, G., 253
Flodérus, U-M. See Pandis, N., 163
Forman, M.L. See Persad, R.V., 121
Fox, H. See Hale, R.J., 233
Fox, H. See Wilkinson, N., 285
Fukuda, K. See Sugimori, H., 179
Fulcheri, E. See Lapertosa, G., 33

Gaggini, C. See Scambia, G., 253
George, M. See Vermorken, J.B., 248
Geyer, H. See Kommoss, F., 147
Ghazal Aswad, S. See Grimshaw, R.N., 15
Giron, D.J. See Nahhas, W.A., 259
Gleeson, N., Gonslaves, R., McGuinness, E. & Bonnar, J. Plasminogen activators in endometrial adenocarcinoma, 223
Gonsalves, R. See Gleeson, N., 223
Grant, P. See Quinn, M.A., 239
Greggi, S. See Benedetti Panici, P., 133
Greggi, S. See Vermorken, J.B., 248
Grimshaw, R.N., Ghazalaswad, S. & Monaghan, J.M. The role of ano-vulvectomy in locally advanced carcinoma of the vulva, 15
Grimshaw, R.N. See Murdoch, J.B., 105
Gusterson, B.A. See Wilkinson, N., 285
Gyllensten, U. See Chetsanga, C., 209

Haapasalo, H., Collan, Y. & Atkin, N.B. Major prognostic factors in ovarian carcinomas, 155
Hachisuga, T. See Sugimori, H., 179
Hale, R.J., Buckley, C.H., Fox, H., Wilcox, F.L., Tindall, V.R. & Logue, J.P. The morphology and distribution of lymph node metastases in stage IB/IIA cervical carcinoma: relationship to prognosis, 233
Hale, R.J., Wilcox, F.L., Buckley, C.H., Tindall, V.R., Ryder, W.D.J. & Logue, J.P. Prognostic factors in uterine cervical carcinoma: a clinicopathological analysis, 19
Harrison, D.J. See Rahilly, M., 268
Hayashi, Y. See Sugimori, H., 179
Heim, S. See Pandis, N., 163
Heydarfadai, M. See Petru, E., 9
Hirakawa, T. See Imachi, M., 113
Holland, D.R., Le Riche, J., Swenerton, K.D., Elit, L. & Spinelli, J. Flow cytometric assessment of DNA ploidy is a useful prognostic factor for patients with granulosa cell ovarian tumors, 227
Hopkins, M.P. & Morley, G.W. Squamous cell cancer of the cervix: prognostic factors related to survival, 173

Hoskin, P.J. & Blake, P.R. Cis-platin, methotrexate and bleomycin (PMB) for carcinoma of the cervix: the influence of presentation and previous treatment upon response, 75
Hoskins, P.J., O'Reilly, S.E. & Swenerton, K.D. The 'failure free interval' defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: relevance to therapy and new drug testing, 205

Imachi, M., Tsukamoto, N., Shimamoto, T., Hirakawa, T., Uehira, K. & Nakano, H. Clear cell carcinoma of the ovary: a clinicopathologic analysis of 34 cases, 113
Imachi, M., Tsukamoto, N., Shimamoto., T., Kamura, T. Saito, T. & Nakano, H. Treatment of patients with advanced ovarian carcinoma with massive pleural effusions, 263
Iwasaka, T. See Sugimori, H., 179

Jakobsen, A., Bichel, P. & Stornes, I. Prognostic significance of DNA index in advanced ovarian cancer, 195
Jakobsen, A. See Bichel, P., 199
Ji, H. X., Syrjänen, S., Klemi, P., Chang, F., Tosi, P. & Syrjänen, K. Prognostic significance of human papillomavirus (HPV) type and nuclear DNA content in invasive cervical cancer, 59

Kamura, T. See Imachi, M., 263
Kawarabayashi, T. See Sugimori, H., 179
Kelly, K. See Redman, C.W.E., 215
Kernohan, N.M. See Blessing, K., 81
Kjorstad, K.E. See Raju, K.S., 69
Klemi, P. See Ji, H.X., 59
Kommoss, F., Pfisterer, J., Geyer, H., Thome, M., Sauerbrei, W. & Pfleiderer, A. Estrogen and progesterone receptors in ovarian neoplasms: discrepant results of immunohistochemical and bichemical methods, 147

Lahousen, M. See Petru, E., 9
Landoni, F. See Vermorken, J.B., 248
Lanman, J.T. Jr. See Steller, M.A., 141
Lapertosa, G., Baracchini, P., Cabiddu, F., Fulcheri, E., Pedullà, F. & Ragni, N. Effectiveness of immunohistochemical techniques in the detection of lymph node micrometastases of cervical squamous cell carcinoma, 33
Lawton, F.G. See Redman, C.W.E., 215
Le Riche, J. See Holland, D.R., 227
Lickrish, G.M. See Bryson, S.C.P., 25
Logue, J.P. See Hale, R.J., 19, 233
Luesley, D.M. See Redman, C.W.E., 215

Mancuso, S. See Benedetti Pancini, P., 133
Mancuso, S. See Scambia, G., 253
Mandahl, N. See Pandis, N., 163
McGuinness, E. See Gleeson, N., 223
Miller, I.D. See Blessing, K., 81
Mitelman, F. See Pandis, N., 163
Monaghan, J.M. See Grimshaw, R.N., 15
Monaghan, J.M. See Murdoch, J.B., 105
Moradi, M.M. See Carter, J., 243
Morley, G.W. See Hopkins, M.P., 173
Moskovic, E., Wiltshaw, E., Blake, P. & Parsons, C. Monitoring patients with ovarian carcinoma: the relationship of serum CA125 levels to CT scanning, 125
Murdoch, J.B., Grimshaw, R.N. & Monaghan, J.M. Loop diathermy excision of the abnormal cervical transformation zone, 105
Murphy, K.J. See Prefontaine, M., 169

Nahhas, W.A., Connelly, P.J., Giron, D.J. & Agostini, H.J. Acute short-term effects of the inhalation of CO_2 laser smoke on Syrian hamsters, 259
Nakano, H. See Imachi, M., 113, 263
Nieberg, R.K. See Takami, C.Y., 97
Norström, A. The use of ultrasound in the identification and treatment of lymphocysts after radical hysterectomy, 275

O'Connell, G.J. See Prefontaine, M., 169
O'Reilly, S.E. See Hoskins, P.J., 205
Olafsson, J.H. See Sigurdsson, K., 49
Ormerod, M. See Tonkin, K.S., 185
Ørntoft, T.F. See Bichel, P., 199

Pandis, N., Heim, S., Willén, H., Bardi, G., Flodérus, U-M., Mandahl, N. & Mitelman, F. Histologic-cytogenetic correlations in uterine leoimyomas, 163
Parsons, C. See Moskovic, E., 125
Pecorelli, S. See Trimbos, J.B., 89
Pecorelli, S. See Vermorken, J.B., 248
Pedullá, F. See Lapertosa, G., 33
Persad, R.V. & Forman, M.L. An analysis of the determinants of negative cone biopsies, 121
Petru, E., Pickel, H., Heydarfadai, M., Tamussino, K., Lahousen, M. & Schaider, H. Experience with stromal tumors and germ-cell tumors of the ovary, 9
Pettersson, B. See Chetsanga, C., 209
Pettersson, U. See Chetsanga, C., 209
Pfisterer, J. See Kommoss, F., 147
Pfleiderer, A. See Kommoss, F., 147
Piccarts, M.J. See Vermorken, J.B., 248
Pickel, H. See Petru, E., 9
Planner, R.S. See Quinn, M.A., 239
Prefontaine, M., O'Connell, G.J., Ryan, E. & Murphy, K.J. Is there a role for CA-125 in monitoring patients with early endometrial cancer?, 169

Quinn, M.A., Rome, R.M., Grant, P. & Planner, R.S. High-dose medroxyprogesterone acetate in advanced ovarian cancer, 239

Ragni, N. See Lapertosa, G., 33
Rahilly, M., Al Nafussi, A. & Harrison, D.J. Distribution of glutathione S-transferase isoenzymes in primary epithelial tumors of the ovary, 268
Raju, K.S., Kjorstad, K.E. & Abeler, V. Prognostic factors in the treatment of stage 1B adenocarcinoma of the cervix, 69
Redman, C.W.E., Blackledge, G., Luesley, D.M., Lawton, F.G., Kelly, K. & Chan, K.K. An assessment of peritoneal lavage fluid CA125 as a tumor marker in epithelial ovarian cancer, 215

Rome, R.M. See Quinn, M.A., 239
Rotmensz, N. See Vermorken, J.B., 248
Ryan, E. See Prefontaine, M., 169
Ryder, W.D.J. See Hale, R.J., 19

Saemundsson, H. See Sigurdsson, K., 49
Saito, T. See Imachi, M., 263
Sauerbrei, W. See Kommoss, F., 147
Scambia, G., Benedetti Panici, P., Battaglia, F., Ferrandina, G., Gaggini, C. & Mancuso, S. Presence of epidermal growth factor (EGF) receptor and proliferative response to EGF in six human ovarian carcinoma cell lines, 253
Scambia, G. See Benedetti Panici, P., 133
Schaider, H. See Petru, E., 9
Shimamoto, T. See Imachi, M., 113, 263
Sigurdsson, K., Benediktsdottir, K., Snorradottir, M., Saemundsson, H., Olafsson, J.H. & Einarsson, G.V. Cervical intra-epithelial neoplasia and koilocytotic lesions of the lower genitalia in an Icelandic population, 49
Snorradottir, M. See Sigurdsson, K., 49
Soper, J.T. See Steller, M.A., 141
Spinelli, J. See Holland, D.R., 227
Steller, M.A., Soper, J.T., Szpak, C.A., Lanman, J.T. Jr & Clark-Pearson, D.L. The importance of determining karotype in premenarchal females with gonadal dysgerminoma: two case reports, 141
Stornes, I. See Bichel, P., 195
Sugimori, H., Kawarabayashi, T., Iwasaka, T., Fukuda, K., Hachisuga, T. & Hayashi, Y. Colposcopic assessment of stage I cervical cancer, 179
Swenerton, K.D. See Holland, D.R., 227
Swenerton, K.D. See Hoskins, P.J., 205
Syrjänen, K. See Ji, H.X., 59
Syrjänen, S. See Ji, H.X., 59
Szpak, C.A. See Steller, M.A., 141

Takami, C.Y., Nieberg, R.K. & Berek, J.S. Correlation of endocervical curettage with subsequent cone biopsy in the investigation of abnormal cervical cytology, 97
Tamussino, K. See Petru, E., 9
ten Bokkel Huinink, W.W. See Vermorken, J.B., 248
Thomas, G.M. & Dembo, A.J. Is there a role for adjuvant pelvic radiotherapy after radical hysterectomy in early stage cervical cancer?, 1
Thomas, G.M. See Bryson, S.C.P., 25
Thome, M. See Kommoss, F., 147
Tindall, V.R. See Hale, R.J., 19, 233
Todd, N. See Wilkinson, N., 285
Tonkin, K.S., Berger, M. & Omerod, M. Epidermal growth factor receptor status in four carcinoma of the cervic cell lines, 185
Tosi, P. See Ji, H.X., 59
Trimbos, J.B., Bolis, G. & Pecorelli, S. The surgical staging of ovarian cancer – current practice in 15 European countries, 89
Tsukamoto, N. See Imachi, M., 113, 263
Twiggs, L.B. See Carter, J., 243

Uehira, K. See Imachi, M., 113

Van de Wiel, H.B.M. See Weijmar Schultz, W.C.M., 37
van der Burg, M.E.L. See Vermorken, J.B., 248
Vermorken, J.B., Landoni, F., Pecorelli, S., Piccart, M.J., van der Burg, M.E.L., ten Bokkel Huinink, W.W., George, M., Greggi, S. & Rotmensz, N. Phase II study of vindesine in disseminated squamous cell carcinoma of the uterine cervix: an EORTC Gynecological cancer Cooperative Group study, 248

Weijmar Schultz, W.C.M., Van de Wiel, H.B.M. & Bouma, J. Psychosexual functioning after treatment for cancer of the cervix: a comparative and longitudinal study, 37
Wilcox, F.L. See Hale, R.J., 19, 233
Wilkinson N., Todd, N., Buckley, C.H., Gusterson, B.A. & Fox, H. An immunohistochemical study of the incidence and significance if C-erbB-2 oncoprotein overexpression in ovarian neoplasia, 285
Willén, H. See Pandis, N., 163
Wiltshaw, E. See Moskovic, E., 125

Keyword index

adenocarcinoma, 223
adenocarcinoma of cervix, 69
anal, 15
ano-vulvectomy, 15

biochemistry, 147
borderline tumor, 268

CA-125, 169, 199
CA125, 279
cancer, 125
cancer cervix, 173
carcinogenesis, 268
carcinoma, 15, 268
carcinoma *in situ*, 49
carcinoma of the cervix, 248
cell lines, 185
c-erbB-2 oncoprotein, 285
cervical cancer, 37, 59, 75, 179, 275
cervical carcinoma, 19, 233
cervical intra-epithelial neoplasia, 105, 121
cervical smear, 209
cervix, 97, 185
cervix dysplasia, 49
cervix neoplasm, 209
chemotherapy, 9, 75, 125, 263
chromosomes, 163
cisplatin resistance, 205
clear cell carcinoma, 113
colposcopy, 49, 121, 179
condylomata accuminata, 49
cone biopsy, 97
CT scanning, 125
cystadenoma, 263
cytogenetics, 163
cytology, 97

DNA index, 195
DNA ploidy, 227
drug resistance, 268
dysgerminoma, 141

early ovarian cancer, 89
ECC, 97
EGF, 253
EGF receptor, 253
endometrial cancer, 169
endometrium, 223
epidemiology, 49
epidermal growth factor receptor (EGFR), 185
epithelial ovarian cancer, 279

failure free interval, 205
flow cytometry, 59, 185, 227
follow-up, 169

germ-cell tumors, 9
glutathione S-transferase, 268
gonadal gysgenesis, 141
gonadoblastoma, 141
granulosa cell tumors, 227
gynecologic malignancies, 133
gynecologic surgery, 133

histochemical distribution, 199
histology, 163
histopathology, 81
HPV infection, 59
hormone receptors, 147
hormone therapy, 239
human papillomavirus, 209

immunocytochemistry, 185
immunohistochemistry, 33, 147

karyotype in germ cell tumors, 141
keratin antibodies, 33

laser plume, 259
laser therapy, 259
leiomyoma, 163
loop diathermy excision, 105
lymph node metastases, 233
lymph node micrometastases, 33
lymphadenectomy, 9
lymphocysts, 275

malignancy grading, 155
malignant melanoma, 81
marker, 169
mass screening, 49
metastatic, 75
mitotic index, 155
morphometry, 155
mucinous cystadenoma, 243

negative cone biopsy, 121
neo-adjuvant, 75
neoplasm, 125

ovarian cancer, 195, 215, 239, 253, 263
ovarian carcinoma, 147
ovarian germ cell tumors, 141
ovarian neoplasia, 285
ovarian neoplasms, 9
ovary, 113, 125
ovary carcinoma, 155, 199

para-aortic lymphadenectomy, 133
pelvic lymphadenectomy, 133
perianal, 15
phase II, 248
pleural effusion, 263
polymerase chain reaction, 59, 209
prognosis, 69, 81, 155, 195, 199, 233, 279
prognostic factors, 19, 59, 227
prognostic groups, 25
pseudomyxoma peritonei, 243
psychosexuality, 37

recurrence, 69
recurrent, 75

scatchard analysis, 185
serous adenocarcinoma, 113
serum CA125, 125
sexual functioning, 37
sexual rehabilitation, 37
squamous cell, 248
squamous cell cancer, 173
squamous cell carcinoma, 33
staging of ovarian cancer, 89
static DNA-cytometry, 155
stromal tumors, 9
surgical staging, 89
surgical techniques, 133
survival, 69, 279

tissue plasminogen activator (t-PA), 223
treatment, 69
tumor markers, 215

ultrasound, 275
urokinase (u-PA), 223
uterine cervix, 33

vindesine, 248
vulva, 15, 81
vulvar cancer, 25